410 results
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics, Inc.
8 Aug 24
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
4:10pm
expenses are comprised of research and development (R&D) expenses and general and administrative (G&A) expenses. Total operating expenses … Ended June 30,
REVENUES:
Collaboration revenues
Royalties, license and other revenues
Total revenues
OPERATING EXPENSES:
Cost of sales
Research
424B5
LCTX
Lineage Cell Therapeutics, Inc.
14 May 24
Prospectus supplement for primary offering
4:36pm
intend to use the net proceeds from this offering for working capital and general corporate purposes, including research and development expenses … for working capital and general corporate purposes, including research and development and capital expenditures. We may also use a portion of the net proceeds
8-K
EX-99.1
135ubzrkh0
9 May 24
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:10pm
424B5
rbqt7d4phs631fijm6
22 Mar 24
Prospectus supplement for primary offering
4:32pm
8-K
EX-99.1
81obmmp
7 Mar 24
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
424B5
wk9p63 lt
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-99.1
k9r t71jl4jj6myeg7
6 Feb 24
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
9:20am
8-K
8arknkork7
6 Feb 24
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
9:20am
8-K
EX-99.1
npp5sg97ts q9ozdso
9 Nov 23
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
b4b4ihj4g
10 Aug 23
LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL
4:10pm